Angiotensin-(1–7): pharmacological properties and pharmacotherapeutic perspectives
D Iusuf, RH Henning, WH van Gilst… - European journal of …, 2008 - Elsevier
Therapeutic modulation of the renin–angiotensin system is not complete without taking into
consideration the beneficial effects of angiotensin-(1–7) in cardiovascular pathology …
consideration the beneficial effects of angiotensin-(1–7) in cardiovascular pathology …
Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats
T Wu, Z Dong, J Geng, Y Sun, G Liu, W Kang… - European Journal of …, 2011 - Elsevier
Recently studies indicated that valsartan could prevent the progression of heart failure
caused by diabetic cardiomyopathy (DCM), while the mechanisms were still poorly …
caused by diabetic cardiomyopathy (DCM), while the mechanisms were still poorly …
Thermal behavior and phase identification of Valsartan by standard and temperature-modulated differential scanning calorimetry
M Skotnicki, A Gaweł, P Cebe… - Drug Development and …, 2013 - Taylor & Francis
Thermal behavior of angiotensin II type 1 (AT1) receptor antagonist, Valsartan (VAL), was
examined employing thermogravimetric analysis (TGA), standard differential scanning …
examined employing thermogravimetric analysis (TGA), standard differential scanning …
Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases
SA Yarows - Expert Review of Cardiovascular Therapy, 2010 - Taylor & Francis
Chronic activation of the renin–angiotensin–aldosterone system (RAAS) plays a key role in
the development of hypertension, and cardiac and renal diseases. RAAS inhibitors, such as …
the development of hypertension, and cardiac and renal diseases. RAAS inhibitors, such as …
Evaluation of pharmacokinetic interactions between the new SGLT2 inhibitor SHR3824 and valsartan in healthy Chinese volunteers
Y Huang, R Liu, Y Wang, G Liu, C Wang, X Chen… - Clinical Therapeutics, 2022 - Elsevier
Purpose Hypertension is often observed in patients with diabetes, and the progression of
diabetic nephropathy is closely related to blood pressure elevation. Thus, the effects of …
diabetic nephropathy is closely related to blood pressure elevation. Thus, the effects of …
Strategic design and clinical evaluation of a fixed-dose combination tablet comprising valsartan, amlodipine, rosuvastatin and ezetimibe for patients with hypertension …
Purpose The objective of this study was to design a fixed-dose combination (FDC) tablet
with minimal interaction of valsartan, amlodipine, rosuvastatin and ezetimibe to improve …
with minimal interaction of valsartan, amlodipine, rosuvastatin and ezetimibe to improve …
益心舒胶囊治疗慢性充血性心力衰竭的临床研究
宋海萍， 赵国定 - 中西医结合心脑血管病杂志, 2009 - cqvip.com
目的评价益心舒胶囊治疗慢性充血性心力衰竭(CHF) 的临床疗效和安全性. 方法将146 例CHF
患者随机分为益心舒胶囊组(A 组, 110 例) 和对照组(B 组, 36 例), 两组均应用洋地黄, 利尿剂 …
患者随机分为益心舒胶囊组(A 组, 110 例) 和对照组(B 组, 36 例), 两组均应用洋地黄, 利尿剂 …
Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin‐induced diabetic rats
P Chan, IM Liu, TF Tzeng, TL Yang… - Diabetes, Obesity and …, 2007 - Wiley Online Library
Aims: We investigated the mechanism (s) by which valsartan, a selective antagonist of
angiotensin subtype 1 (AT1) receptor, decreased plasma glucose in streptozotocin (STZ) …
angiotensin subtype 1 (AT1) receptor, decreased plasma glucose in streptozotocin (STZ) …
缬沙坦治疗36 例高血压合并心力衰竭的临床疗效研究
伍三妹 - 中国实用医药, 2010 - cqvip.com
目的观察缬沙坦治疗高血压合并心力衰竭的临床疗效. 方法选择72 例高血压合并心力衰竭的
住院患者, 随机分为治疗组与对照组各36 例, 对照组给予降压, 强心, 利尿等常规治疗 …
住院患者, 随机分为治疗组与对照组各36 例, 对照组给予降压, 强心, 利尿等常规治疗 …
缬沙坦治疗慢性充血性心力衰竭的疗效分析
于秀清， 高云华， 石国刚 - 现代中西医结合杂志, 2009 - cqvip.com
目的观察缬沙坦治疗慢性充血性心力衰竭(CHF) 的临床疗效及安全性. 方法将74 例慢性CHF
患者随机分成2 组, 均予基础治疗, 治疗组给予口服缬沙坦80 mg/d. 2 组疗程为1 个月 …
患者随机分成2 组, 均予基础治疗, 治疗组给予口服缬沙坦80 mg/d. 2 组疗程为1 个月 …